psx:substance/mdma/section/receptor-pharmacology.full@1
sectionreferenced by edges — no row of its own
Closure of psx:substance/mdma/section/receptor-pharmacology.full@1: 53 upstream, 21 downstream.
psx:substance/mdma/section/receptor-pharmacology.full@1
├─ informed_by claim/4171e15d-4d40-4eee-bced-8ce8f99111aa Claim in receptor-pharmacology — inconclusive working
├─ informed_by claim/57725aea-c9e5-4804-a19a-b5db96379651 Claim in receptor-pharmacology — inconclusive working
├─ informed_by claim/7fa7c5f9-3052-4a45-b143-dae98ac48ce3 Claim in receptor-pharmacology — inconclusive working
├─ used src/doi:10.1038/s41386-024-01972-6 Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants
├─ used src/pmid:15831439 Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters
├─ used src/doi:10.1124/mol.60.6.1181 Amphetamine, MDMA, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor
├─ used src/pmid:16911722 The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents
├─ used src/doi:10.1111/j.1360-0443.2010.02948.x Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin
├─ used src/doi:10.1002/cpt.565 Potential Psychiatric Uses for MDMA
├─ used src/doi:10.1038/s41591-021-01336-3 MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
├─ used src/doi:10.1038/s41591-023-02565-4 MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
├─ used src/doi:10.1007/s40263-025-01162-y MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward
├─ used src/url:f04836dd1b8db9ed Australia TGA rescheduling MDMA to Schedule 8 for PTSD treatment
├─ used src/doi:10.1124/pr.55.3.3 The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")
├─ used src/pmid:12404538 Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies
├─ used src/pmid:10917407 Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects
├─ used src/pmid:16510474 MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress
├─ used src/pmid:15910012 Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe
├─ used src/doi:10.2165/11584550-000000000-00000 Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans
├─ used src/doi:10.1002/hup.2811 Serotonin transporter availability, neurocognitive function and their correlation in abstinent 3,4-methylenedioxymethamphetamine users
├─ used src/doi:10.1017/S0033291716000258
├─ used src/pmid:16541247 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings
├─ used src/pmid:17152992 The origin of MDMA ("ecstasy")--separating the facts from the myth
├─ used src/url:3f26882996785e95 MDMA scheduling history and DEA Schedule I placement
├─ used src/doi:10.1177/0269881112464827 A randomized, controlled pilot study of MDMA-assisted psychotherapy for treatment of resistant, chronic PTSD
├─ used src/pmid:2457659 Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity
├─ used src/doi:10.1177/0269881110378371 The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
├─ used src/doi:10.1007/s00213-019-05249-5 MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials [RETRACTED]
├─ used src/doi:10.1523/JNEUROSCI.1171-11.2011
├─ used src/pmid:15228154 Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition
├─ used src/pmid:11106307 The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of MDMA ('Ecstasy') in healthy volunteers
├─ used src/doi:10.1016/j.psyneuen.2014.04.006 Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans
├─ used src/doi:10.1038/npp.2014.12 Effects of MDMA and Intranasal oxytocin on social and emotional processing
├─ used src/doi:10.1007/s00213-018-5010-9 Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study
├─ used src/doi:10.1016/j.euroneuro.2026.112802 Efficacy of MDMA-assisted therapy for PTSD: A systematic review and meta-analysis
├─ used src/doi:10.1002/npr2.12485 MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials
├─ used src/doi:10.1017/S1461145713001132
├─ used src/doi:10.1038/s41386-019-0402-z Effects of MDMA on attention to positive social cues and pleasantness of affective touch
├─ used src/doi:10.1177/0269881120926673 Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment
├─ used src/doi:10.1038/npp.2017.171 MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections
├─ used src/doi:10.1016/j.drugalcdep.2024.111139 MDMA impairs cognitive function during withdrawal via activation of the arachidonic acid cascade in the hippocampus
├─ used src/doi:10.1093/brain/awaf391 Memory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities
├─ used src/doi:10.1111/j.1360-0443.2010.03252.x Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs
├─ used src/doi:10.1523/jneurosci.1659-20.2020 Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
├─ used src/pmid:12468674 The 'ecstasy' hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine
├─ used src/doi:10.7759/cureus.90328 Intracranial Pressure-Guided Therapy in MDMA-Induced Cerebral Edema: A Case Report
├─ used src/pmid:12297982 Acute liver failure following the use of ecstasy (MDMA)
├─ used src/doi:10.3310/hta13050 The harmful health effects of recreational ecstasy: a systematic review of observational evidence
├─ used src/doi:10.1016/j.psychres.2025.116929 Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using WHO pharmacovigilance database (VigiBase)
├─ used src/pmid:14758467 Study of the behavioural responses related to the potential addictive properties of MDMA in mice
├─ used src/doi:10.1007/s40263-025-01256-7 Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances
├─ derived_from gen/94f0fc50-a7d2-455a-9334-d823dfdfab88 Generation — pipeline-v5
└─ generated_by pub/bf000688-f775-46ad-81be-8604a8e3d69f Publication — backfill
├─ used version/1 Revision 1
├─ used claim/2280a6e4-1bd3-4364-8093-a7f07a4f4f34 Claim in pharmacology — inconclusive working
├─ used claim/89059e4e-9207-4398-b0fc-9439fa42a057 Claim in pharmacology — inconclusive working
├─ used claim/64ddcd16-87fe-4b26-a636-b54994078da6 Claim in comparative-pharmacology — inconclusive working
├─ used claim/d6291d2b-e4bf-4522-ba1a-dbcad90bac64 Claim in chemistry — inconclusive working
├─ used claim/a2d32e95-b9e2-45a7-a7f0-85e39278e4fe Claim in pharmacokinetic-detail — inconclusive working
├─ used claim/6935d50c-e982-428d-9232-961e0217a4e9 Claim in comparative-pharmacology — inconclusive working
├─ used claim/49d4dd5e-51ad-4094-b8ca-a3022f1a9f0a Claim in neuroscience — inconclusive working
├─ used claim/f8b1cb4e-822c-4ba2-b452-06c3ecfdb71e Claim in summary — inconclusive working
├─ used claim/865ab307-59cb-42e3-922a-76af2e17c3c7 Claim in pharmacology — inconclusive working
├─ used claim/f98bcf86-e7e9-4f3f-adbc-da295a4bb282 Claim in pharmacology — inconclusive working
├─ derived_from issue/notice@49a1e353e4c4 Issued notice
├─ derived_from issue/info_card@12f7eb336495 Issued info_card
├─ derived_from issue/emergency@47cf1475db8d Issued emergency
├─ derived_from issue/info_card@30fcaed19743 Issued info_card
├─ informed_by section/pharmacology.full@1
├─ informed_by section/comparative-pharmacology.full@1
├─ informed_by section/chemistry.full@1
├─ informed_by section/pharmacokinetic-detail.full@1
├─ informed_by section/neuroscience.full@1
└─ informed_by section/summary.full@1
… closure truncated at 200 nodesindented by distance from this node, not by parentage